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1. Introduction
There is a continual and increasing demand for crystalline
molecular materials with specific, fit-for-purpose physico-
chemical properties.[1–6] Interest in polymorphism, crystalli-
zation, and (in industry) in robust process development has
surged over the last two decades,[7,8] as evidenced by the
immense growth in knowledge concerning the design, prep-
aration, and characterization of crystalline materials.[9] This
expanding interest and demand for promising materials drives
investigations of the solid form (i.e. polymorphs, solvates,
hydrates, and amorphous materials) landscapes[8, 10] of poten-
tially relevant compounds, with the goal of identifying the
optimally performing solid among them.
A broad range of crystallization techniques is generally
employed to search for the most stable crystal form in
hundreds or (in some cases) thousands of experimental
attempts.[11] New crystal forms can, however, emerge unex-
pectedly long after the carefully designed and executed
screening experiments are completed. Such a sudden emer-
gence of a new crystal form can be unsettling and problem-
atic, especially in the late stages of a product development or
even following launch, because the newly emerged form can
exhibit different (possibly undesired) properties. Equally
disruptive is the emergence of a thermodynamically more-
stable crystal form, in accord with OstwaldÏs Rule of Stages,[12]
concurrent with the disappearance of the less-stable known
forms that signal a loss of control of the production process.
While it may create roadblocks in the development process or
even the marketed product of the solid form of a compound of
interest, the consequences of the appearance of a new form
are not necessarily negative. The serendipitous appearance of
a new form may provide a substance with improved charac-
teristics.
Unfortunately, our current understanding of the mecha-
nisms and processes involved in the nucleation and growth of
crystals is still insufficient for precise control over the
formation or disappearance of a polymorph (or any other
crystal form).[13, 14] Nearly twenty years ago, Dunitz and
Bernstein presented an overview of the disappearing poly-
morph phenomenon[15] that has captivated and intrigued
solid-state scientists since. In their review, Dunitz and
Bernstein voiced their belief that crystal forms do not
disappear permanently; on the contrary, once a solid form
has been obtained, in principle it can always be reproduced if
the right experimental conditions are met.[15–18] In the same
spirit as the earlier survey, this Review aims to discuss
selected recent occurrences of disappearing polymorphs and
of elusive crystal forms that have not only triggered the
curiosity of researchers, but have also affected the business of
pharmaceutical and health care companies. These examples
illustrate how apparently stable polymorphs can suddenly
disappear, and how elusive crystal forms can be prepared
given the availability of conditions specifically designed to
promote their formation. The uncontrolled loss of a crystal
form can have serious consequences, and there is thus an
urgent need to develop methods that provide absolute control
over crystal nucleation and growth,[13, 14] which is still an art,
rather than a routine procedure.[19]
In addition to citing examples of disappearing polymorphs
from the literature and our own laboratories, the 1995 review
dealt with a number of issues that are still the subjects of
debate. There have also been a number of patent litigations in
which the same issues have arisen and have been interpreted
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Nearly twenty years ago, Dunitz and Bernstein described a selection
of intriguing cases of polymorphs that disappear. The inability to
obtain a crystal form that has previously been prepared is indeed
a frustrating and potentially serious problem for solid-state scientists.
This Review discusses recent occurrences and examples of disap-
pearing polymorphs (as well as the emergence of elusive crystal forms)
to demonstrate the enduring relevance of this troublesome, but always
captivating, phenomenon in solid-state research. A number of these
instances have been central issues in patent litigations. This Review,
therefore, also highlights the complex relationship between crystal
chemistry and the law.
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variously by the courts. We will deal initially with those
aspects of the subject and follow with the descriptions of
a number of recent cases of disappearing polymorphs (and
other crystal forms), as well as further details on some of
those previously cited.
2. Disappearing Polymorphs—The Concept and
Misconceptions
One of us (J.B.) recently recounted the genesis of the 1995
review,[20] which was based on earlier cases in the laboratories
of both Bernstein and Dunitz as well as additional examples
we had encountered in the course of our involvement in the
ranitidine hydrochloride litigations. In the twenty-year
interim we have experienced numerous additional examples
in which the phenomena described therein were either
misinterpreted or misunderstood. Hence, we review some of
those here.
2.1. The Concept
As we described in the section of the 1995 review headed
“Vanishing Polymorphs”, a disappearing polymorph refers to
a crystal form that has been prepared at least once and whose
existence has been established experimentally by some
observation or measurement. Subsequent attempts to prepare
the same crystal form by the same procedure lead to
a different crystal form, alone or together with the old one.
If a mixture appears in the first instance, then very often in
subsequent preparations the new form dominates and the old
form is no longer obtained.
The phase rule limits to one the number of stable crystal
forms that may exist under a specific set of conditions. The
old—“disappeared”—form is generally less stable than the
new one under those specific conditions. In thermodynamic
terms, it is metastable, although that does not necessarily
imply that it would spontaneously convert into a more stable
form; it only means that it is at a higher energy minimum than
the most stable state. To invoke a familiar example: diamond
is metastable with respect to graphite; nevertheless, as is
widely advertised, “diamonds are forever”.
The fact that a crystal form once existed, but is now
difficult to prepare by the same method that was previously
used, does not mean that it is impossible to prepare again. It
has not been relegated to the “crystal form cemetery”.[21]
Every crystallization is a competition between kinetic and
thermodynamic factors. As noted in the last sentence of the
1995 review, “it is always possible to obtain [the old form]
again; it is only a matter of finding the right experimental
conditions”—thermodynamic and kinetic.
Recovering a crystal form that has disappeared may
require considerable time and effort and invoke some
inventive and creative chemistry. The examples given below
will demonstrate the kinds of strategies that have been
employed to recover crystal forms that have disappeared.
2.2. Seeds and Seeding
The 1995 review also contains a section headed “Seeding”.
Intentional seeding is a well-known technique for inducing
crystallization and is widely used, especially in the pharma-
ceutical industry. Unintentional seeding arises from the
presence of small amounts—indeed, in principle one particle
is sufficient—of the solid material that is present even as
a contaminant. As we noted earlier, “Unintentional seeding is
often invoked as an explanation of phenomena which are
otherwise difficult to interpret. We shall argue in favor of this
explanation, although there is no consensus about the size and
range of activity of such seeds, which have never actually been
directly observed.”[15]
The situation this statement describes has led to consid-
erable controversy, particularly in the framework of patent
litigations involving crystal forms. That controversy very
much represents the clash between the cultures of science and
the law, and in light of that controversy it seems appropriate,
indeed compelling, to put the phenomenon of unintentional
seeding into a proper scientific perspective in this Review.
Virtually every chemist has at some time attempted to
crystallize a compound. Crystallization is perhaps the classic
method of purification, and the technique is one of the first
mentioned in purification methods in any undergraduate
organic chemistry laboratory textbook. Practicing chemists
soon learn, often simply by experience, that it is frequently
very difficult to crystallize a newly synthesized substance,
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while subsequent crystallizations are considerably more
facile. The situation was documented over half a century
ago by Wiberg in his classic text “Laboratory Technique in
Organic Chemistry” in the section entitled “Inducing Crys-
tallization”: “When a compound is prepared for the first time
in a laboratory, it is often observed that it is relatively difficult
to effect crystallization. However, once the compound has been
obtained in the crystalline state, it is usually easy to effect
crystallization, and it has been suggested that after initial
crystallization crystal nuclei are present in the laboratory and
induce crystallization”.[22] In the current context those nuclei
are unintentional seeds.
Many laymen are initially skeptical about a phenomenon
caused by particles that cannot be seen, although very few
would accept an invitation for a casual—and unprotected—
visit to the pneumonia ward at their local hospital. The
approximate limit of visual detection for the naked eye is
a crystal that weighs approximately 10¢6 g. We pointed out
earlier that a speck of that size contains approximately 1016
molecules and while there are various estimates of the size of
a critical nucleus that could act as a seed even the largest—
a few million molecules[23]—would mean that an invisible
particle could contain up to 1010 of such unintentional seeds.
Where do these microscopic particles come from? As
noted elsewhere, depending on our location, the air contains
a vast number of submicroscopic particles. For a normal urban
environment there are approximately 106 airborne particles of
0.5 micrometer diameter or larger per cubic foot, the number
being reduced by an order of magnitude in an uninhabited
rural environment. A sitting individual generates roughly one
million dust particles ( 0.3 micrometer diameter) per minute
(a visible particle is usually  10 micrometers).[24] Clean
rooms for various purposes (e.g. surgery, biological or
pharmaceutical preparations, semiconductor fabrication)
employ very sophisticated technology to remove these
particles and to prevent subsequent contamination. There-
fore, the possible presence of seeds of a newly formed
polymorph in a laboratory, a manufacturing facility, or any
location having been exposed to that form cannot be casually
dismissed; indeed its presence would be hard to avoid. In his
comprehensive monograph on crystallization, Mullin notes
that, “Atmospheric dust frequently contains particles of the
crystalline product itself, especially in industrial plants or in
laboratories where quantities of the material have been
handled…Once a certain crystalline form has been prepared
in a laboratory or plant, the working atmosphere inevitably
becomes contaminated with seeds of the particular material.”[23]
So much for the atmosphere. What about the crystallizing
medium, usually a solution? The normal determination that
dissolution has been completed is made by visual inspection.
If the solution is clear to the human eye all the solute is
assumed to be in solution. Mullin has also pointed out that
“aqueous solutions as normally prepared in the laboratory
may contain > 106 solid particles per cm3…”.[23] These can be
impurities or particles of the solute that have not undergone
complete dissolution, and can serve as seeds for the subse-
quent crystallization.
The presence and influence of microscopic seeds and their
influence on crystallization is thus well established. Never-
theless, it is difficult for many who lack practical laboratory
experience to accept their existence. In the history of
chemistry there have been many instances of inductive
reasoning in understanding chemical phenomena. The exis-
tence of atoms was proposed and accepted for nearly two
hundred years before an atom was actually “seen”. Yet no
chemist doubts the existence of atoms or the ability to make
and break bonds between them.
The presence and influence of seeds may be invoked to
explain the disappearance of one crystal form at the expense
of a new form. In such a case, the unintentional seeding by the
new form may be quite aggressive, preventing the crystal-
lization of the old form. However, there is no intrinsic reason
why every system is influenced by such aggressive uninten-
tional seeding. There are many known examples of multi-
crystalline materials in which the various forms can be
prepared and maintained in the known presence of other
forms. As for polymorphism in general, every system is
unique and must be individually studied and characterized to
understand how to prepare and characterize each form.
2.3. “Universal Seeding”
The publicity surrounding some cases of aggressive
unintentional seeding led to discussions, particularly in legal
circles, of the alleged phenomenon of universal seeding—that
is, in some cases of disappearing polymorphs, when the old
form could not be made by the old process somehow, there
was an implication that the entire universe must be seeded. To
put the matter to rest it is important to quote a footnote from
the 1995 review: “The claim for Ðuniversal seedingÏ, taken
literally, is obviously absurd. After all, the universe is estimated
to contain about a millimole of stars, so one seed per star (per
solar system)—not much—would need about 100 kg of the
compound in question (Mr 100)”.
A number of cases of aggressive seeding have attained
considerable notoriety, and these will be described below. In
instances where various locations at considerable distance
have become “infected” with a new form within a relatively
short time, it has been possible to trace the source of the
seeding in successively affected locations.
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3. Recent Instances of Disappearing Polymorphs
and Elusive Crystal Forms
This section describes several of the most (in)famous
recent cases of disappearing polymorphs and other crystal
forms. In addition, in relation to the sudden and unexpected
disappearance of a well-known crystal form, we consider it
particularly relevant to describe cases where elusive crystal
forms, believed to be non-existent, were prepared.
3.1. Ranitidine Hydrochloride
In the early 1970s, James Black at (then) Smith, Kline &
French identified the histamine type 2 (H2) receptor and from
the preparation of a series of H2-receptor antagonists
developed the first antiulcer drug, cimetidine (TagametÔ),
for which he won the 1988 Nobel Prize in Medicine. H2-
receptor antagonists are among the miracle drugs of the 20th
century. Prior to their introduction (and the subsequent entry
of proton pumps) there were millions of sufferers of peptic
ulcers worldwide with a significant number of fatalities; since
their introduction, the surgical procedure for removing peptic
ulcers has essentially been eliminated from the modern
medical school curriculum.
The dramatic success of cimetidine led to industry-wide
efforts to develop additional H2-receptor antagonists. In 1977,
Allen &Hanbury (then a part of Glaxo Group Research, now
GSK) developed ranitidine and its hydrochloride (Figure 1a),
for which a US patent was issued in 1978.[25] The preparation
of the hydrochloride following the multistep synthesis of
ranitidine base is given in “Example 32” of the patent
(Figure 1b).
Subsequent development of the drug over nearly four
years involved batch scale-ups to a multi-kilogram scale in the
companyÏs pilot plant by employing essentially the chemistry
described in Example 32.[10] The batch prepared on April 15,
1980 failed the quality control IR analysis, which exhibited
a hitherto unobserved sharp peak at 1045 cm¢1, and suggested
the formation of a new crystal form designated Form 2. The
subsequent four batches exhibited increasing amounts of
Form 2 and the same process no longer produced the (now
designated) Form 1. Considerable efforts to revert to the
production of Form 1 by essentially the same process were
unsuccessful. Thus, this is clearly a case of a disappearing
polymorph. Serendipitously, Form 2 had considerably
improved filtering and drying characteristics which, in
addition to the novelty of the new polymorph, formed the
basis for a patent application, granted in 1985.[10] The crystal
structures of both forms have been subsequently determined;
both forms crystallize in the monoclinic P21/n, space group,
wherein the nitroethenediamine moiety of the ranitidine
cations displays different conformations and degrees of
disorder (Figure 1c).[26–28] This is thus also an example of
conformational polymorphism.[29]
Glaxo launched ranitidine hydrochloride in 1984 as
ZantacÑ and by 1992 it was the worldÏs best-selling drug at
US$3.44 billion per year, when sales for the next largest drug
(BayerÏs Adalat ProcardiaÑ) were about half that amount.[30]
In accord with the terms of the 1984 Hatch–Waxman Act in
the US, by 1990 a number of generic drug companies were
planning to enter the market with Form 1 in anticipation of
the 1995 expiration of the Form 1 patent. Attempts to make
Form 1were based on carrying out Example 32. As transpired
in the course of the subsequent litigations, essentially all of
those attempts started with commercial Form 2 ; hence, at the
very least Form 2—thus seeds of Form 2—were present in the
environment in which attempts to follow Example 32 were
being carried out.
Following numerous attempts to prepare Form 1 accord-
ing to Example 32, which led almost exclusively to Form 2,
the Canadian generic firm Novopharm claimed that Glaxo
had never made Form 1 and sought approval from the Food
and Drug Administration (FDA) to market Form 2. Glaxo
aimed to prevent Novopharm (and others) from entering the
market with Form 2 by suing them for the infringement
(actually, virtual infringement under the Hatch–Waxman
Act) of their Form 2 patent. Novopharm admitted infringe-
ment of Form 2, but argued that the Form 2 patent was
inherently anticipated in the Form 1 patent, since their
attempts to prepare Form 1 according to Example 32 led to
Figure 1. a) Molecular structure of ranitidine hydrochloride. b) Exam-
ple 32 from patent US 4128658A (“Aminoalkyl furan derivatives”), the
apparently straightforward procedure for the preparation of Form 1 of
ranitidine hydrochloride. c) Overlay of the ranitidine cation from
Form 1 (blue) and Form 2 (red). Form 2 features a disordered nitro-
ethenediamine moiety.
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Form 2. Novopharm contended that the experimental proce-
dures underpinning the Form 1 patent were flawed, to which
Glaxo responded that the oppositionÏs experiments were
contaminated with seed crystals and hence not a faithful
reproduction of Example 32 [Clearly, there were no seeds of
Form 2 anywhere prior to April 15, 1980].
The legal concept of inherency in the United States
implies a consistent result of a process, that is, it must be
invariable or inevitable that one obtains the later claimed
result to establish inherency. Thus, to support its case against
inherent anticipation, in principle Glaxo had to demonstrate
that Example 32 did not inevitably or invariably yield Form 2
but could in fact yield Form 1.
To do so, in the course of the August 1993 trial, the
notebooks of David Collin, who been the first to prepare
ranitidine hydrochloride were examined, cross-examined, and
compared to the wording in Example 32. CollinÏs notebooks
contain three slightly different examples. As is common for
a laboratory notebook, the texts are not word-for-word
identical nor is any one identical to the language in
Example 32, and there was much discussion over the differ-
ences and what they would mean to a practicing chemist (one
“skilled in the art” in patent lexicon).
In addition, one of GlaxoÏs witnesses, Sir Jack Baldwin of
the University of Oxford, in 1993 had two of his senior
postdoctoral fellows complete the entire synthesis of raniti-
dine base according to the Form 1 patent followed by the
reproduction of Example 32 using that prepared base. They
also obtained Form 1 three times.
Those six instances of the preparation of Form 1 according
to Example 32 were sufficient to overcome the inherency
argument. The Form 2 patent was found to be valid and
Novopharm (and others) were restricted from marketing
Form 2 prior to its anticipated expiration in 2002.
Legal footnotes. A number of litigation cases ensued. It
was surprising that Glaxo could no longer make Form 1 in the
original pilot plant, but even so, at the time, the concept of
disappearing polymorphs and the role of unintentional
seeding were treated with skepticism by those who had no
personal experience of the phenomenon. For instance,
counsel for Novopharm included the following in his opening
statement to the court:[31]
“ThereÏs also testimony in this case which is under
a protective order from a third party pharmaceutical company
that did the same thing. They reproduced example 32 and got
Form 2. So we have six different locations or incidents where
example 32 had been reproduced to yield Form 2, not Form 1.
WhatÏs GlaxoÏs response to this? Seed crystals, theyÏre in the
air. You canÏt see them. You canÏt smell them. You canÏt taste
them. You also canÏt detect them but theyÏre there, and these
seed crystals fall out of the sky, and theyÏre very intelligent
because they know when youÏre running one of these example
32 experiments. They fall out of the sky and they fall in your
reaction beaker and it causes not Form 1 to be produced, but
Form 2, and thatÏs why when we run this experiment today we
get the Form 2 product and not the Form 1.”
“Well, I submit that if one believes in Santa Claus we might
believe in these seed crystals, but if weÏre beyond that, weÏre not
going to believe in these seed crystals, and even if you do, the
techniques that were used in these reproductions would,
without a doubt, exclude these seed crystals because these
seed crystals to survive in the method that has been used for
these reproductions have to defy standard chemical princi-
ples”.
Some excerpts from the cross-examination of one of
NovopharmÏs witnesses regarding seeding:
Question (cross-examining attorney): “I think the issue of
seeding is one that I would have expected to come from
a crystallographer. Have you made a study of the subject of
seeding?”
Answer : “IÏve found in my experiments that I canÏt see any
seeding effects.”
Question : “You found that you canÏt see. My question was,
have you done a study of the science of seeding which takes in
account the myriad of works of those who can see. Have you
made such a study?”
Answer : “IÏve done a literature search to see if a theoretical
phenomena (sic) like the hypothetical theory of universal
seeding could be found in all of the chemical abstract literature,
and the only references I found to something called universal
seeding had to do with entries like, universal prevention of
fungus on weed seeds by using certain different fungicides.
ThatÏs the only type of reference I could come up with when I
scanned the chemical literature.”
Question : “…Now, did you go to any meeting of profes-
sional crystallographers or did you consult crystallographers to
see whether there was a body of knowledge that you hadnÏt
found?”
…Answer : “I reported my negative findings to the
[attorneys] .”
3.2. Ritonavir
Perhaps the most notorious recent example of a disap-
pearing polymorph is that of ritonavir (Figure 2a), an
antiviral compound marketed by Abbott Laboratories in
1996 as NorvirÑ in the form of semisolid gel capsules for the
treatment of the acquired immune deficiency syndrome
(AIDS). The capsules were based on the only known crystal
form, Form I, discovered during the development process. In
1998, however, a new and significantly less-soluble polymorph
of ritonavir unexpectedly precipitated out in the semisolid gel
capsules, thereby leading to failed dissolution tests for the
capsule.[32, 33] Subsequent studies showed that the new form,
referred to as Form II, exhibited a significantly lower
solubility in hydroalcoholic solutions than the marketed
Form I.[33] In addition, it was found that Form II rendered
Form I unobtainable in any laboratory to which Form II had
been introduced. There was even speculation that the
conversion of Form I into Form II in the laboratory was
facilitated simply by the presence of an individual who had
previous exposure to Form II (or the contaminants that were
subsequently shown to enable the formation of Form II). As
a result of these events, ritonavir had to be temporarily
withdrawn from the market.[34]
Crystallographic analyses showed that the crystal struc-
ture of Form I is characterized by ritonavir stacks resembling
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a b-sheet structure (Figure 2b).[32] The structure is sustained
by N-H(amide)···O(amide) and O-H(hydroxy)···N(thiazole)
hydrogen bonds (with first-order graph set N1=C(4)C11)
[35]).
The crystal structure of Form II, on the other hand, is
comprised of heavily hydrogen-bonded one-dimensional
ritonavir stacks (Figure 2b).[36] Each molecule in the stack is
hydrogen bonded to two other molecules through a total of
eight N-H(amide)···O(amide), N-H(amide)···O(hydroxy),
and O-H(hydroxy)···O(amide) hydrogen bonds (N1=
C(6)C(9)C(11)C(12)).[32, 35] The higher calculated crystal den-
sity of Form I suggested it is also the more stable crystal
form.[37] In addition, a survey of the Cambridge Structural
Database (CSD) indicated that Form I ritonavir exhibits
a statistically more favorable conformation of the carbamate
moiety.[32] The analysis was in agreement with an NMR study
in solution that revealed the existence of two conformers in
solution in a ratio of roughly 99:1. The conformers could not
be unambiguously resolved as Forms I and II, but it was noted
that the observed 99:1 relationship of the two conformers is
consistent with the initial discovery of a single polymorph,
that is, Form I.[32] The higher stability of Form II was, in the
end, attributed to the formation of a hydrogen-bond pattern
wherein, unlike in Form I, “all of the strong hydrogen bond
donors and acceptors have been satisfied”.[33] This argument is
consistent with the observation that Form II has a higher
melting point and heat of fusion (ca. 125 8C, 87.8 Jg¢1) than
Form I (ca. 122 8C, 78.2 Jg¢1).[33]
A recent logistic regression hydrogen-bonding propensity
study involving Forms I and II (using the CSD as data source)
reported that the kinetically more favored Form I displays
a statistically doubtful hydrogen-bond pattern. Specifically, it
was found that Form I entails statistically improbable hy-
droxy-thiazoyl and ureido-ureido interactions—despite the
hydrogen-bond donorÏs and acceptorÏs availability for the
realization of high-propensity hydrogen bonds.[38]
The origin of Form II was initially unclear, as it was
established that ritonavir solutions would crystallize as
Form II only if seeded with Form II—even at amounts as
low as 1 ppm. Heterogeneous nucleation was identified as
a possible cause of the formation of Form II. Specifically, it
was found that ritonavir degrades in a base-catalyzed reaction
to form a carbamate-bearing product (Figure 2c) structurally
related to the conformation of ritonavir in Form II.[32] It was
also found that the degradation product forms very rapidly
and that, consistent with its greater stability, it exhibits a lower
solubility than ritonavir. It was concluded that the degrada-
tion product had possibly crystallized out of a ritonavir bulk
solution, which had experienced solvent loss, and then acted
as a seed for Form II.
Eventually, consistent with the closing statement in the
1995 review, extensive studies demonstrated that the crystal-
lization of Form I could be achieved under controlled
conditions in laboratories that had previously been exposed
to Form II.[33] Ritonavir was finally reformulated and
approved in 1999 before being placed back on the
market.[39] It was estimated that the company had experienced
losses in revenue of over US$250 million.[34]
A more recent study attempted a high-throughput poly-
morph screen of ritonavir to comprehensively explore the
compoundÏs structural diversity. The screen included about
2000 crystallization experiments and resulted in the finding of
three new crystal forms in addition to Forms I and II—
namely, a metastable polymorph, a trihydrate, and a forma-
mide solvate.[40] These findings highlight the necessity of
utilizing a variety of crystallization methods, in this particular
case, high-throughput screening, combined with carefully
designed crystallization experiments for the retrieval of the
relevant structures associated with the structural landscape[41]
(also referred to as packing landscape[13]) of a molecule.
Public relations footnote. As noted, AbbottÏs initial
encounter with Form II and its inability to produce Form I
led to the disappearance of the drug NorvirÔ from the market,
leaving tens of thousands of AIDS patients without medi-
cation. This led to a serious public relations problem for
Abbott. To allay public concern, the company held a number
of interviews and press conferences, at which senior Abbot
officials appeared in order to answer questions. The tran-
scripts were originally published on the website[42] of the
International Association of Physicians in AIDS Care, but no
longer appear there. Some excerpts vividly portray the
situation that can arise when a disappearing polymorph is
encountered:
“There was no gradual trend. Something occurred that
caused the new form to occur…There was no early warning.”
“We, quite honestly, have not been able to pinpoint the
precise conditions which led to the appearance of the new
Figure 2. a) Molecular structure of ritonavir. b) Crystal structures of its
Form I (left) and Form II (right). c) Formation of the presumed
heteronuclear seed of ritonavir Form II through a base-catalyzed
reaction.
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crystal form. We now know that the new form is, in fact, more
stable than the earlier form, so nature would appear to favor
it…Form II is new.”
“We did not know how to detect the new form. We did not
know how to test for it. We did not know what caused it. We
didnÏt know how to prevent it. And we kept asking the
question, why now?…We did not know the physical properties
of the new form…We did not know how to clean it, and we did
not know how to get rid of it.”
“…our initial activities were directed toward eliminating
Form II from our environment. Then we finally accepted that
we could not get rid of Form II. Then our subsequent activities
were directed to figuring out how to live in a Form II world.”
“This is why all of us at Abbott have been working
extremely hard throughout the summer [of 1998], often around
the clock, and sometimes never going home at night. We have
been here seven days a week and we will continue to do so. We
have cancelled vacations and asked our families for their
understanding and support. This is not an issue that we take
lightly.”
“There were several sub-teams of three to 600 people per
team working full time in different areas. We also called on as
many resources as we could.”
“We tried everything. We conducted countless experiments.
We reconditioned our facilities. We rebuilt facilities and new
lines. We looked at alternative sites. We visited a number of
[other] organizations around the world…to see if we could
start clean in a new environment free of Form II.”
“In a matter of weeks—maybe five or six weeks, every place
the product was became contaminated with Form II crystals.”
Question: “You are a large multinational company. Your
scientists are obviously smart. How could this happen?”
Answer : “A companyÏs size and the collective IQs of their
scientists have no relationship to this problem…This obviously
has not happened to every drug. But it has happened to other
drugs.”
3.3. Paroxetine Hydrochloride
Paroxetine hydrochloride is a serotonin re-uptake inhib-
itor used for the treatment of depression. The chemical
compound paroxetine was initially developed by the Danish
company Ferrosan in the 1970s. Beecham (now part of
GlaxoSmithKline, GSK) purchased the rights to paroxetine in
1980 and undertook development of the hydrochloride salt of
paroxetine as a drug product. Beecham developed a process
that produced paroxetine hydrochloride in a crystalline form
that was later referred to as the “anhydrate” crystalline form.
Late in 1984, however, in the course of pilot plant scale-up,
the “hemihydrate” crystalline form suddenly appeared at two
Beecham sites in the UK within a few weeks of each other.
The new hemihydrate form was designated Form 1 and the
previously existing anhydrate was labeled Form 2 (Figure 3).
The hemihydrate was not hygroscopic and exhibited
handling properties superior to those of the anhydrate. In
1986 GSK applied in the US for a patent on the hemihydrate,
which was granted in 1988.[43] Paroxetine hydrochloride was
finally marketed as the hemihydrate form in 1993 under the
name PaxilÔ.[10, 44]
During the 1980s in the course of the development of the
compound for eventual launch, Beecham investigated the
properties of both the anhydrate and hemihydrate. They
determined that in the presence of water (or humidity) the
anhydrate undergoes a conversion into the hemihydrate,
a process that is accelerated by temperature, pressure, and the
presence of seeds of the hemihydrate.[45] In BeechamÏs
experience, it was difficult to avoid the conversion of the
anhydrate to hemihydrate in the presence of water or
humidity in a facility seeded with hemihydrate.
In 1998, Apotex, a Canadian generic drug manufacturer,
filed an Abbreviated New Drug Application (ANDA) with
the FDA to market a generic version of the off-patent
anhydrous paroxetine hydrochloride (Form 2). The hemi-
hydrate patent would expire in 2006. Again, under the terms
of the Hatch–Waxman Act GSKopposed the Apotex request,
arguing that the anhydrous form (Form 2) would convert into
the hemihydrate (Form 1). GSKÏs argument was based, in
part, on evidence that Apotex had begun development of its
anhydrous product by bringing the hemihydrate into its
manufacturing facility, thus providing the seeds that had been
shown to be a factor in the conversion. In addition, there was
contact with water in the manufacturing of the active
pharmaceutical ingredient (API), in the formulation, and in
the production of the final water-based coating process of the
pill, as well as the use of pressure in the last processing step.
A trial was held in February, 2003 in the US Federal
Court, Chicago, with Judge Richard Posner presiding.[46]
Judge Posner is one of the most cited judges in the history
of the US federal courts, having written over 2500 published
decisions, and as a Professor of Law at the University of
Chicago has published nearly 40 books.
GSKÏs assertion that Apotex would infringe the hemi-
hydrate patent was based on GSK and Apotex documents
showing that many of ApotexÏs anhydrate batches had
Figure 3. a) Molecular structure of the paroxetine cation. b) Crystal
structure of Form 1 viewed along the crystallographic c axis. c) Crystal
structure of Form 2 viewed along the crystallographic b axis. The
positions of the water hydrogen atoms in Form 1 were not determined
(green spheres: chloride anions; red spheres: water molecules).
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exhibited evidence of conversion: there were batches of
anhydrate that converted almost entirely into hemihydrate
when stored at 40 8C and 75% humidity within one month.
This Apotex experience was bolstered by the results of GSKÏs
testing of ApotexÏs API and its formulated tablets. Further-
more, ApotexÏs specification for release of bulk material was
based on a visual method of comparing spectral data that
could not detect less than 5–8% of infringing hemihydrate in
the bulk API.
In its defense, Apotex argued that seeding is “junk
science”, not widely accepted in the scientific community and
that the mechanism of the role of seeds and the conversion is
not understood. Moreover, it claimed that the supplier of the
bulk API had improved the process to avoid contact with
water and was storing the material in improved storage bags,
less permeable to water.
In response, GSK argued that Apotex produced the
tablets under conditions of normal humidity and sprayed the
tablets with an 88% water-based aqueous coating.
Judge Posner rejected ApotexÏs contentions concerning
seeding, stating “that there is no scientific basis for believing
that seeding occurs…is obviously wrong.” In his ruling on the
case he found that ApotexÏs anhydrate converts into the
hemihydrate (in accord with the earlier publication by
SmithKline Beecham scientists) and that it “may continue
until it reaches 100 per cent.” He also found that ApotexÏs limit
of detection of the hemihydrate in an allegedly anhydrous
material was 5–8%, but he did not rely on this finding in
determining whether Apotex was infringing the GSK patent.
Nevertheless, Judge Posner ultimately ruled in ApotexÏs
favor. Claim 1 of GSKÏs hemihydrate patent recited “Crys-
talline paroxetine hydrochloride hemihydrate”. Judge Posner
ruled that this was valid, but that ApotexÏs product would not
likely infringe the patent because Apotex would not be
making it intentionally, and not “in any commercially
significant quantity”. Judge Posner interpreted Claim 1 as
limited to only “commercially significant amounts of hemi-
hydrate” and explained that the concentration would have to
be in the “high double digits to contribute any commercial
value”. He further stated that GSK had not established that
Apotex would be marketing material with high double-digit
concentrations of hemihydrate and that Apotex would not
benefit monetarily from the hemihydrate.
Judge Posner thus found the patent valid, but also that
Apotex would not infringe it. The case was appealed to the
US Federal Circuit Court, which handles all patent appeals in
the United States. The Federal Circuit ruled in favor of
Apotex, but for different reasons than those invoked by
Posner. The Federal Circuit also found that Judge PosnerÏs
claim construction was incorrect, and that the claim properly
covered any amount of hemihydrate. The Federal Circuit,
however, reasoned that Claim 1must, therefore, be invalid for
inherency because if anhydrate converted into the hemi-
hydrate now, it must have converted into hemihydrate in at
least small amounts in the prior art. The US Supreme Court
refused to hear the case.
Many aspects of those rulings, and the way they were
subsequently reported in the trade press, deal with important
aspects of disappearing polymorphs and seeding. Details are
provided in the Addendum of this Review.
A very recent study demonstrates that it is not possible to
claim that all the probable crystal forms of a compound have
been found or even fully characterized. Pina et al. showed
that Form 2, which had initially been described as a hygro-
scopic anhydrate, was in fact a nonstoichiometric hydrate,[47]
which dehydrates and rehydrates very easily, despite a lack of
continuous channels in the crystal lattice. The higher stability
of Form 1was justified by a higher number of hydrogen bonds
being involved in retaining the water molecules in the crystal
lattice,[47] although no quantitative estimates of the relative
stabilities were calculated.
3.4. Paroxetine Methane Sulfonate (Paroxetine Mesylate)
The market success of paroxetine hydrochloride (world-
wide sales of US$3.2 billion in 2001) led many pharmaceut-
ical companies to search for additional crystal forms. One
approach is to prepare a different salt. In the mid-1990s
SmithKline Beecham (now GSK) in the UK and Synthon in
the Netherlands independently succeeded in making the
mesylate (methanesulfonate) salt of paroxetine. Considering
the nature of the chemistry, it is not surprising that the
procedure leading to the salt is similar in the two patents. The
first US patent was issued to Synthon on 23.02.1999. Another
US patent was issued to SmithKline Beecham nearly
15 months later on 16.05.2000.
How could two patents be issued for the same salt? One
clear possibility is that they are two different crystal forms of
the same salt, which should be discernible from the analytical
data presented in the patent. Table 1 contains a comparison of
the relative data from the two patents. Clearly, the only data
that can be compared are those from the IR spectra. The IR
data from the two patents are given in Table 2. Comparison of
the two peak lists indicates that they do not characterize the
Table 1: Summary of analytical data from two patents on paroxetine
mesylate.
Synthon SmithKline Beecham
melting point 142–1448C 143–1468C
XRPD – peak list
IR spectrum
(peak list)
KBr pellet:
18 peaks in specifications
8 peaks[a] in
Claim 1 (4 cm¢1)
NMR solution –
[a] Nujol: 12, 18, or 35 peaks; ATR: 32 peaks; KBr: 35 peaks.
Table 2: Comparison the IR peak lists reported in the two patents on
paroxetine mesylates [cm¢1] .
Synthon SmithKline Beecham
3023, 2900, 2869, 2577, 1615, 1515, 1500,
1469, 1208, 1169, 1100, 1038, 962, 931, 838,
777, 546, 531
1603, 1194, 1045, 946,
830, 601, 554, 539
(4 cm¢1)
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same crystal form. In the course of litigation it became
apparent that every reported synthesis of paroxetine mesylate
(since the issuance of the Synthon patent) has yielded the
peaks found in the SmithKline Beecham patent. There are
only two explanations for this situation: 1) the Synthon form
is a disappearing polymorph, having been prepared and
characterized at least once, and subsequent preparations and
crystallizations led to the SmithKline Beecham form, or 2) the
Synthon data are in error.
A series of litigations on the issues associated with the
paroxetine mesylate reported in these two patents (and their
European equivalents) failed to achieve a legal consensus on
the issue. Some of those litigations are summarized in Table 3.
Although not reported in the literature, the paroxetine
mesylate case is an outstanding example that underpins the
necessity to thoroughly investigate, characterize, and docu-
ment APIs and speciality chemicals.
3.5. Rotigotine
Rotigotine (Figure 4a) is a non-ergot-derived dopamine
agonist initially prescribed for the treatment of ParkinsonÏs
disease, and later approved for moderate-to-severe cases of
restless-legs syndrome. It is marketed by UCB under the
name NeuproÔ, and administered through a transdermal
patch to minimize the unpleasant side effects of the drug.[48]
NeuproÔ was approved by the European Medicines
Agency (EMEA) for use in Europe and then by the FDA
for the US market in 2007. In 2008, a previously unknown and
thermodynamically more stable polymorph emerged in the
NeuproÔ patches, in the form of “snow-like crystals”. The new
polymorph was unanticipated and unexpected, as the drug
had been established since the 1980s and no polymorphism
had been observed during drug development or there-
after.[48, 49] While the new polymorph (Form II) exhibited no
reduction in efficacy, physicians, distributors, pharmacists, and
patients were advised to refrigerate their NeuproÔ stocks,
since refrigerated storage significantly reduced crystallization
rates. UCB continued to supply NeuproÔ in Europe, but
specific batches were recalled and replaced by batches that
were refrigerated immediately after manufacture. While
there was “only” a minor disruption in NeuproÔ supply in
Europe, the situation was much more serious in the US, where
NeuproÔ became temporarily unavailable. After the FDA
recommended reformulation of the drug, UCBÏs new
NeuproÔ formulation that did not require refrigeration was
approved by the agency in 2012.
The origin of the more stable Form II of rotigotine is not
known, but it is reasonable to speculate that the polymorphic
transformation was suddenly triggered by an event, or an
impurity, in the patch or the drug itself. The initially observed
and long-known polymorph (Form I) crystallizes in the
tetragonal P43 space group,
[50] while Form II crystallizes in
the orthorhombic P212121 space group.
[51] Both polymorphs
feature disordered thiophene moieties and similar hydrogen-
bonding patterns of one-dimensional zigzag chains of O-H···N
hydrogen bonds [N1=C(8)
[35]]. However, Form II is more
dense (and thus likely more stable, according to the Burger–
Ramberger density rule[37]) and accompanied by a conforma-
tional change caused by the adjustment of the torsion angle
between the thiophene and alkyl moieties.
3.6. DMP543
DuPont entered the development of pharmaceutical
agents for the treatment of AlzheimerÏs disease in the 1980s.
Extensive studies finally resulted in the development of
DMP543—an acetylcholine release enhancer with the desired
potency, plasma duration, and brain penetration properties
(Figure 5). It became evident in the early stage of the drugÏs
development that DMP543 was very susceptible to poly-
Table 3: Summary of the litigations between SmithKline Beecham Corp. and Synthon Pharmaceuticals Ltd.
Forum Case No. Disposition Patents Disputed
United States
Middle District of
North Carolina
(M.D.N.C.)
1:00CV01179 Settlement filed
Dec. 30, 2003
US Pat. No. 4,721,723, issued Jan. 26, 1988,
titled “Anti- Depressant Crystalline Paroxetine Hydrochloride Hemihydrate”
US Pat. No. 6,063,927, issued May 16, 2000,
titled “Paroxetine Derivatives”
US Pat. No. 6,113,944, issued Sept. 5, 2000,
titled “Paroxetine Tablets and Process to Prepare Them”
The Hague T 0885/02–3.3.1. Ruling for Synthon,
European Patent revoked
EP0970955, published Dec. 1, 2000, titled “Paroxetine Menthanesulfonate”
House of Lords [2005] UKHL 59 Ruling for Synthon,
UK patent invalid
UK Pat. No. 2336364, filed on Apr. 23, 1999,
published May 10, 2000, titled “Paroxetine Salt”
Figure 4. a) Molecular structure of rotigotine and b) overlay of rotigo-
tine molecules extracted from the crystal structures of Forms I and II
(shown in red and blue, respectively). Only the major occupation site
of the disordered thiophene moiety is shown.
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morphism, as 17 polymorphs were produced and character-
ized by powder X-ray diffraction.[52] The authors attributed
the ability of DMP543 to form such a large number of
polymorphs to the conformational flexibility of its pyridyl
groups, although it has recently been determined that there is
no statistical correlation betweenmolecular flexibility and the
tendency to polymorphism.[29] It was found that some
polymorphs interconvert easily on heating. But more intrigu-
ingly, apparently identical recrystallization conditions would
not always lead to the formation of the same polymorph. A
robust method for the crystallization of a single polymorph
was finally established using an ethyl acetate/heptane solvent
mixture. The first process batch, however, yielded a previously
unknown polymorph (#18). Although this procedure initially
appeared robust, researchers were concerned that the prep-
aration of the solvent mixture might not be reproducible and
that differential solvent evaporation rates could, in future
experiments, trigger the formation of other new and possibly
unwanted solid forms. This led to the decision to produce
a crystallization procedure based on a single solvent. It was
then found that isopropanol reliably produced another new
polymorph (#19, Form A) in high yields, and this polymorph
was finally chosen for further development.
After the initial batch of Form A was prepared, the
synthetic procedure for DMP543 was refined, and this
modified procedure was utilized to prepare the second
batch. The synthesis of the second batch began in Deepwater,
NJ (USA), but was completed at a different location, namely
the Merck Frosst Centre in Dorval, Quebec, where the
clinical trials were intended to be conducted. During the
course of the synthesis, the anthrone alkylating agent had to
be purified three times (by two recrystallizations and one
chromatographic purification) before the compound was
finally recrystallized from isopropanol to achieve 98.5%
purity, which was the lowest purity grade specification
acceptable for clinical trials. A second recrystallization of
the solid, however, resulted (to everybodyÏs surprise) in the
formation of yet another new polymorph (#20, Form B).
Three subsequent recrystallizations were performed using the
new form, utilizing seeds of Form A with the hope of
producing a large batch of Form A. All three recrystallization
experiments yielded Form B. Attempts to prepare Form A at
DuPont in Deepwater resulted exclusively in the formation of
Form B—very shortly after Form B was discovered at the
Merck Frosst site in Dorval.[52, 53]DuPont was never again able
to produce Form A. Form B turned out to be the most stable
of all polymorphs according to thermal analysis and was,
therefore, selected as the preferred crystalline form of
DMP543 for production.[53] Although no new polymorphs
were found in the following five years, DMP543 was never
commercialized.
3.7. LAB687
Another extraordinary account of the unpredictability of
polymorphism comes fromNovartis, and involves a compound
internally identified as LAB687 (Figure 6a),[54] an inhibitor of
the microsomal triglyceride transfer protein developed for the
control of triglyceride and LDL-cholesterol levels.[55] Two
polymorphs were found during drug development: the
original synthetic route yielded Form B, while a gram-scale
synthesis based on a different synthetic procedure led to the
formation of Form A.
A subsequent polymorph screen was conducted using
a 98.9% pure batch of Form A, which yielded a third
polymorph (Form C), as well as a toluene solvate. Two
solvates based on heptane methylcyclohexane were then later
discovered during the development of seeding-based crystal-
lization procedures for the reproducible larger-scale (100 g)
synthesis of Forms A and C. Although Forms A and C were
found to have similar intrinsic solubilities and physical
stabilities, Form C was selected for further development
because it had better filtration and flow properties than
Form A. Remarkably, once Forms A and C were discovered,
Form B could not be reproduced. A new polymorph, Form D,
unexpectedly appeared when the crystallization process for
Form C was scaled up for a multi-kilogram synthesis. Oddly,
once Form D emerged, Forms A and C could no longer be
prepared. It was assumed that Form D appeared due to
a change in the impurity profile of the LAB687 batches during
the implementation of a new and more-efficient phase I
synthetic route for one of the LAB687 intermediates. Indeed,
this route led to the formation of a dimeric urea byproduct
(i.e. an impurity, Figure 6b) that was not present in batches
obtained using other synthetic routes, although no direct
Figure 6. a) Molecular structure of LAB687, and b) the dimeric urea
impurity believed to be responsible for the formation of LAB687
Form D.
Figure 5. Molecular structure of DMP543.
.Angewandte
Reviews
D.-K. Bucˇar et al.
6982 www.angewandte.org Ó 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2015, 54, 6972 – 6993
correlation could be determined between the formation of
this impurity and the appearance of Form D.
3.8. Sulfathiazole
The unexpected formation of polymorphs of the antimi-
crobial compound sulfathiazole (Figure 7a) is also triggered
by impurities or reaction byproducts. Five polymorphs of
sulfathiazole have so far been identified (Figure 7b–f)[56–60] in
addition to over one hundred solvates.[61] The solid-state
chemistry of the sulfathiazole polymorphs has been thor-
oughly analyzed[62, 63] and numerous research groups reported
different methods for the preparation of each polymorph.[62] It
is, however, also reported that some methods cannot be used
with confidence for the formation of phase-pure batches of
the targeted sulfathiazole polymorphs, since different
research groups reported different outcomes using the same
crystallization conditions.
A recent review[64] addressed the widespread belief that
a particular sulfathiazole polymorph is consistently accessible
from a given solvent, and suggested that this view was in fact
misleading. The author shared his personal experience from
over 2000 crystallization experiments involving sulfathiazole
and revealed that all five known polymorphs can be obtained
from nearly every solvent used in his comprehensive studies.
It was also stated that the polymorphs are enantiotropically
related and that the solidÏs treatment after crystallization is
most critical in determining the polymorphic outcome.
Indeed, the sensitivity of the sulfathiazole solid towards
post-crystallization treatment is in keeping with the incon-
sistent results reported in the literature, which shows that the
same (or very similar) crystallization conditions can lead to
the formation of different sulfathiazole polymorphs.
Despite the inconsistencies in the reported crystallization
outcomes, it has been established that the crystallization of
sulfathiazole from water follows OstwaldÏs rule of stages,[12]
whereby the least-stable polymorph (Form I) appears first,
and transforms into Forms II and III before the transforma-
tion ends with the appearance of the thermodynamically
stable Form IV.[63, 65] Notably, it has also been demonstrated
that the transformation (and disappearance) of the metasta-
ble Form I can be suppressed by the presence of impurities in
the crystallization solution. More specifically, a compound
that forms as a byproduct of the sulfathiazole synthesis (i.e.
ethamidosulfathiazole) was used to show that concentrations
as low as 10 mol% stabilize metastable Form I, while
amounts of 0.5–1.0 mol% yielded a mixture of the four
Forms I–IV. Pure solutions, as well as those with an impurity
content of 0.01 mol%, were shown to yield Form IV.[65] The
ability of ethamidosulfathiazole to stabilize Form I was
attributed to its capacity to integrate into the growing crystal
faces of Form I without disrupting crystal growth. The growth
of Forms II, III, and IV, on the other hand, becomes inhibited
once ethamidosulfathiazole becomes attached to their grow-
ing crystal faces.
Although sulfathiazole polymorphs do not tend to “dis-
appear for good” as claimed for some other polymorphs
described in this Review, the sulfathiazole system seems
unique because of its complexity and sensitivity, and high-
Figure 7. a) Molecular structure of sulfathiazole. b) Crystal structures of Form I showing how sulfathiazole builds a three-dimensional hydrogen-
bonded network (left) that is interpenetrated by a two-dimensional hydrogen-bonded network (right). The two networks are built from
crystallographically independent molecules (colored red and blue). c–f) Crystal structures of Forms II–V showing the formation of two-dimensional
hydrogen-bonded networks. The two-dimensional networks in Forms III and V (shown in (d) and (f), respectively) are sustained by two
crystallographically independent sulfathiazole molecules (colored red and blue).
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lights the need to understand how byproducts obtained from
the synthesis of a target compound can profoundly affect its
solid-state chemistry.
3.9. Progesterone
Crystal structure prediction (CSP) has enjoyed a decade
of increasing success rates and an expanding range of
applications in the study of molecules of increasing complex-
ity.[66, 67] A recent study suggested that progesterone (Fig-
ure 8a) may be a useful model compound with which to test
advances in CSP, as a suitable “real” system of pharmaceut-
ical interest.[68] Steroids are the basis of fundamental hor-
mones and many drugs; they have rigid structures, and
progesterone is a relatively simple example of a steroid.
Beyond that, steroids are generally relatively easy to crystal-
lize and they often exhibit polymorphism. Progesterone was
chosen as a model compound for CSP based on the above
criteria, with a supposedly well-understood polymorphic
system documented in the scientific literature stretching
back 70 years.
The predictive studies correctly identified the two known
polymorphs (Forms I[69] and II,[70] Figure 8b,c) in enantio-
morphic space groups. CSP studies also strongly indicated
that there were a number of more-stable centrosymmetric
structures with one at the global minimum. This lowest-
energy structure was ultimately crystallized by mixing natural
(nat) progesterone with its enantiomer ent-progesterone.
When this work was initiated, centrosymmetric structures
were not considered because they do not exist naturally for
this chiral molecule, but the results from the CSP studies were
so compelling that the experimental search for a racemic
structure was undertaken. During the course of this study it
became apparent that the metastable low-melting-point
Form II of nat-progesterone was an example of a disappearing
polymorph, as attempts to make it soon failed and attempted
crystallizations became erratic in their polymorphic outcome.
Attempts were then made to template progesterone with
a structurally related steroid, pregnenolone (Figure 8a),
which resulted in the successful preparation of Form II
along with the concomitant formation of a 1:1 progesterone:
pregnenolone cocrystal.[71] The metastable form produced by
these means was stable for periods ranging from hours to two
or three months!
About this time it transpired that the University of
Innsbruck had samples of both polymorphs in an archive.
Their metastable polymorph had not transformed in over
50 years! The chemical analysis of the long-lasting Form II
sample revealed impurities that were not present in the
sample of Form I, thus highlighting the potential role of
contaminants/additives in stabilizing metastable crystal forms.
Attempts were made to analyze the impurity profiles
associated with the archived samples, with a view to doping
crystallizations involving modern much purer commercial
material. These were unsuccessful owing to the complexity of
the impurity profiles associated with the old samples.[72]
3.10. The Elusive Form II of Aspirin
Aspirin (acetylsalicylic acid, Figure 9a) is a widely used
analgesic, and its antiplatelet activity makes it a commonly
prescribed long-term preventative agent for reducing the risk
of heart attacks and strokes.[73] Although first synthesized
Figure 8. a) Molecular structures of progesterone and pregnenolone.
b) Crystal structure of Form I of progesterone. c) Crystal structure of
Form II of progesterone. d) Crystal structure of the 1:1 progesterone:-
pregnenolone cocrystal (progesterone blue, pregnenolone red). Crystal
structures in (b) and (c) are viewed along the crystallographic a axis.
Figure 9. a) Molecular structures of aspirin and the aspirin anhydrate.
Crystal structures of b) Form I and c) Form II. The crystal structures in
(b) and (c) are viewed along the crystallographic b axis. The inversion
centers are represented with black spheres, while the 21 screw axes are
depicted using green arrows.
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more than 150 years ago, only one polymorph[74] of aspirin
(Form I) was known until 2005. The potential polymorphism
of aspirin was extensively studied and debated in the 1960s
and 1970s,[75] but the existence of another polymorph was not
definitely established with certainty.[76]A study from the early
1980s reported that aspirin, if crystallized in the presence of
aspirin anhydride (Figure 9a), exhibits the characteristic
aspirin Form I diffractogram, along with weak additional
peaks.[77] It was concluded that these are not likely to
correspond to a new aspirin polymorph, but rather belonged
to an impurity in the form of a cocrystal or solid solution
composed of aspirin and salicylic acid.[77,78] It took more than
30 years to discover that these “impurity” peaks are actually
related to another polymorph, Form II.
A computational study published in 2004 predicted that
the known crystal Form I is the most stable, but it also
predicted the existence of a second polymorph that exhibits
virtually the same crystal lattice energy as the known form.[79]
The elusiveness of this polymorph was ascribed to its
predicted low shear elastic constant, which suggests that the
polymorph exhibits an energetic low barrier to transforma-
tion into Form I. A later study concerning aspirin cocrystals
led to the discovery of the new polymorph, Form II.[80] The
Form II solid was obtained in the course of an attempt to
cocrystallize aspirin with levetiracetam in a 1:1 ratio, and
although its structure was derived from crystallographic data
of lower quality,[80, 81] it was in good agreement with the
computationally predicted crystal structure of the elusive low-
energy polymorph. Forms I and II of aspirin are structurally
(and energetically) very similar.[79] Both forms feature
centrosymmetric aspirin dimers held together by the carbox-
ylic acid homosynthon. The dimers form two-dimensional
layers parallel to the crystallographic c axis. The two forms
differ in the relative positions of the neighboring dimer layers,
as well as the symmetry elements between them (Fig-
ure 9b,c).
Soon after the initial discovery of Form II, two studies
provided evidence that the initially reported Form II is in fact
an inter-grown phase[82] containing domains with structural
features corresponding to both Forms I and II.[83, 84] It should
be noted that no solid exhibiting the structural features of
Form II alone could be isolated at that point. It was also
reported that the inter-grown phase could only occasionally
be prepared by recrystallization of freshly synthesized aspirin
from acetonitrile or tetrahydrofuran. Interestingly, commer-
cial samples crystallized under the same conditions only
yielded crystals of Form I. It was then discovered that the
diffractograms of the inter-grown crystals displayed weak
peaks belonging to the aspirin anhydrate, thus indicating that
the anhydrate might have played a significant role in the
formation of the inter-grown phase.[78] Further investigations
demonstrated that the inter-grown crystals can be regularly
prepared using aspirin anhydrate as seed material. It was also
shown that seed quantities of up to 10 wt% yield inter-grown
crystals with a substantial presence of Form II domains.
Finally, the seeding experiments have also established that
phase-pure batches of the elusive Form II can be reliably
prepared if aspirin solutions are seeded with 15 wt% of the
anhydrate.[78]
3.11. The Elusive (caffeine)·(benzoic acid) Cocrystal
Recently, molecular cocrystals have been attracting the
attention of pharmaceutical and materials scientists, primarily
because of their potential ability to alter the physicochemical
properties of molecular compounds[85–97] while maintaining
the pharmaceutical activity of the active pharmaceutical
ingredient. This deepened interest in cocrystals has led to the
development of increasingly sophisticated crystallization
techniques,[98,99] which are generally used during cocrystal
screening in an integrated fashion in the search for new
(co)crystal forms of a drug candidate. When cocrystallization
attempts fail, it is difficult to know whether the failure was
due to poorly chosen experimental conditions or because the
cocrystal simply cannot form based on thermodynamic
considerations, that is, the cocrystal lattice energy is higher
than the lattice energy of the cocrystal components.
Caffeine is one of the most utilized model compounds in
studies of pharmaceutical cocrystals, and has been shown to
engage in cocrystallization with a wide variety of carboxylic
acids;[100,101] despite this, the literature is replete with reports
that caffeine does not form a cocrystal with benzoic
acid.[102,103] For example, a recent study describes the efforts
of four research groups to prepare the elusive cocrystal using
neat grinding, liquid-assisted grinding, and solution-mediated
phase transformation.[104] After all attempts failed, CSP
methods[105,106] were employed to evaluate the potential
existence of a 1:1 (caffeine)·(benzoic acid) cocrystal, and
showed that the formation of the target cocrystal is indeed
thermodynamically favored.
The CSP work also aimed to identify appropriate hetero-
nuclear seeds for the cocrystallization of caffeine and benzoic
acid. It was presumed that a high kinetic barrier hindered the
formation of the cocrystal, and it was proposed that this
barrier could be overcome by introducing a heteronuclear
seed, which matched the target cocrystal structurally or
epitaxially. Fluorinated benzoic acids were used to form
cocrystals based on molecular assemblies similar in shape and
size to those present in the putative (caffeine)·(benzoic acid)
cocrystal.
The rationale behind the use of fluorinated benzoic acids
lay in the relatively small size difference between the van der
Waals radii of hydrogen and fluorine.[107] The strategy was
successful: heteronuclear-seeding experiments yielded the
target cocrystal in all four laboratories where “seedless”
cocrystallization attempts previously failed (Figure 10). Inter-
estingly, once the heteronuclear seeds were introduced to
a laboratory, they—or the seeds of the product cocrystal—
continued to act as long-lasting laboratory “contaminants”
that enabled cocrystallization even when present at undetect-
ably low levels, an observation consistent with WibergÏs
earlier observation.[22]
The quest for the (caffeine)·(benzoic acid) cocrystal
demonstrates the utility of CSP calculations in assessing the
likelihood of cocrystal formation. At the same time, the study
stresses that current cocrystal screening methods need to be
improved to eliminate the occurrence of false negative results
that could impede the development of functional multi-
component crystalline materials. This study highlights the
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gaps in our current understanding of the nucleation process of
cocrystals and of how laboratory contaminants may affect the
outcomes of crystallization experiments.
A related study recently demonstrated that seeding is
indeed a practical method of crystallizing anticipated solids
that are inaccessible at ambient conditions. Specifically,
a monohydrate of the neurotransmitter g-aminobutyric acid
was obtained at high pressure and subsequently recovered at
ambient conditions at which its crystallization was unsuccess-
fully attempted in numerous trials. The high-pressure poly-
morph could then be consistently used to produce the elusive
hydrate at ambient conditions.[108]
4. Recovering Disappeared Polymorphs
As noted above, at any particular temperature and
pressure, the Gibbs Phase Rule permits the existence of
only one thermodynamically stable polymorph of a substance.
However, kinetic stability allows the coexistence of more than
one form. It is, therefore, possible in principle to prepare and
maintain a number of crystal forms at ambient conditions
without limitation.
In many of the cases of disappearing polymorphs
described above, the form that disappeared was the only
one known until a new form appeared—often as a result of
the same procedure that previously led to the now absent
form. In most cases this means that among the known forms,
the new form is the thermodynamically preferred, but not
necessarily the most stable form under those conditions. Since
the disappeared form had been prepared and characterized
(often many times and over long periods of time), it must
occupy its own definite region in phase space, even if it
becomes very difficult to prepare it again. The almost
inescapable conclusion from this situation is that the most
practical strategy for recovering a disappearing polymorph is
to employ kinetic crystallization methods rather than ther-
modynamic crystallization methods. The dominance of a new
form is often also a result of aggressive seeding by that form,
thus indicating that those seeds must be assiduously avoided
to prepare the disappeared form. The following examples will
demonstrate these principles.
One of the first detailed studies of conformational
polymorphism involved the study of dimorphic p,p’-dichloro-
benzylideneaniline.[109,110] Both forms were grown from eth-
anol solutions. The metastable triclinic form initially crystal-
lized as transparent needles with a 4 è long axis parallel to the
needle axis. Cleaving the crystals perpendicular to the needle
axis would induce a transformation to the orthorhombic form
that could be detected by an increasing cloudiness of the
crystal and a concomitant loss of single crystallinity. Over
a relatively short period of time (i.e. a few weeks), as the
amount of the orthorhombic form increased in the laboratory,
it became increasingly difficult to obtain the triclinic form.
The method that finally produced the triclinic form quite
consistently (but not always!) was to prepare a maximally
saturated solution in boiling ethanol (a beaker seemed to
work better than an Erlenmeyer flask) and to immediately
place the solution in a closed desiccator freshly charged with
CaCl2 and minimizing the contact of the solution with the
laboratory atmosphere that no doubt contained seeds of the
orthorhombic form. This provided a kinetically biased
crystallization, combining the high degree of supersaturation
with the fairly rapid cooling and the desiccating power of the
CaCl2. While the triclinic form could be made quite consis-
tently by this method, the eventual solid-to-solid transforma-
tion could not be prevented.
We noted above the notion that a laboratory can become
seeded with a stable form and render it extremely difficult, if
not impossible, to prepare the metastable form in that same
laboratory environment. Essentially two solutions are possi-
ble—but, again, not always successful—to this situation:
1) move to another laboratory (another distant geographical
location may be required) or 2) thoroughly clean the labo-
ratory. We describe an example of each of these solutions.
In 1972, one of us (J.B.) prepared the dimethyl analogue of
the dichlorobenzylideneaniline described above, and found
the cell constants to be identical to those reported by Bîrgi
et al. about four years previously.[111] When we were ready to
carry out the crystal structure analysis a few months later the
crystals had deteriorated, so the compound was recrystallized
using the same ethanol solvent as the previous batch. This
Figure 10. a) Molecular structure of caffeine (caf) and benzoic acid
(BA). b) Cocrystals as heteronuclear seeds: cocrystals composed of
caffeine (caf), 2-fluorobenzoic acid (2FBA), and 2,5-difluorobenzoic
acid (25diFBA). c) Predicted lowest-energy crystal structure of
(caf)·(BA). d) Overlay of the isomorphous lowest-energy predicted and
obtained (caf)·(BA) cocrystal (red: predicted, blue: observed).
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resulted in a new polymorph. Over the next two years,
numerous syntheses and recrystallizations that followed
failed to yield the original crystal form, although a third
polymorph did appear.
At that time we were moving into a new laboratory a few
kilometers distant from the old one where the original
experiments had been done. We hired a new student (by
telephone) and instructed her to use newly purchased
reagents and virgin glassware in the new lab. The original
polymorph was prepared on her first attempt.
The other option to attempt to recover a disappeared
polymorph is to cleanse the laboratory of the culpable crystal
form. Such a strategy was employed by Nielsen and Borka
with benzocaine:picric acid.[112] The material was used as
a pharmacopeial standard in the 1960s. There is a higher
melting (162–163 8C) form that was obtained from the lower
melting (132 8C) form by drying the latter at 105 8C for at least
one hour or by vacuum drying/sublimation. Once the higher
melting form was obtained, the lower melting form could no
longer be prepared. In the authorsÏ words: “As a matter of
curiosity, it ought to mentioned that once the stable modifica-
tion was obtained, the metastable modification could no longer
be isolated…It was found that after discarding all samples,
washing the equipment and laboratory benches and waiting for
8–12 days, the low-melting modification could be isolated
again. This has now been repeated several times in our
laboratories.”[112]
In 1999, we initiated a thorough reinvestigation of this
system based very much on hot-stage microscopy,[16] and in
addition to the two 1:1 complexes we confirmed an earlier
reported 2:1 complex and a hydrate of a 1:1 complex.[113,114] In
a set of carefully designed experiments we first prepared the
low-melting 1:1 form from a saturated aqueous solution at
80 8C, since the hot-stage experiments indicated that the low-
melting form is the stable one above this temperature. Thus,
we avoided the presence of seeds of the high-melting form,
which was subsequently prepared by a non-aqueous gel-
diffusion crystallization with both components dissolved in
a 3:1 CHCl3 :CH3OH solvent mixture. The 2:1 complex was
obtained over a period of four weeks from a 1:1 mixture in
isopropyl alcohol. The 1:1 hydrate was obtained after 48 h
from a saturated aqueous solution in a sealed virgin flask at
20 8C.
The 1995 review described the joint experience (in Zîrich
and Beer Sheva) with p’-methylchalcone. In the 1920s, the
compound was investigated by Weygand for nearly ten years
using thermomicroscopy and summarized in a 1929 review.[115]
For many years it competed for the title of “world record
holder” for the number of reported polymorphs (albeit
lacking structure determinations) of a molecular compound
with 13 forms. Weygand distinguished seven modifications
(called “main forms”) as monotropically related with a high
probability. In our hands, in accord with the finding of
Weygand, once the seeds of the most-stable highest melting
form (m.p. 75 8C) are present in the laboratory it is virtually
impossible to obtain any of the other forms by standard
solution crystallization techniques.
It is well known that the polymorphic form may be
influenced by the reaction mixture, since the material is
crystallizing from a different solution environment.[17, 116] p’-
Methylchalcone[17] is prepared by a simple condensation
reaction, so that some synthetic conditions—at least the
solvent and the temperature—may be readily varied. We
carried out the base-catalyzed condensation reaction using
the appropriate ketone and aldehyde under nine conditions
(three solvents: methanol, ethanol, and 2-propanol; three
temperatures: 20 8C, 4 8C, and ¢13 8C) and obtained five
thermodynamically unstable forms directly from the reaction
mixture.[17] As a consequence of their instability, they were
not easy to handle or characterize, but we did obtain sufficient
evidence to positively identify and distinguish them.
In many of these cases of disappeared polymorphs, if the
old form can be obtained, it often transforms to the new, and
presumably thermodynamically more stable, form. That
situation is by no means universal. For instance, in the case
of ranitidine hydrochloride, in spite of the difficulty of
preparing Form 1 in the presence of Form 2 seeds, the two
forms can exist side by side essentially indefinitely, since there
is no simple mechanism for the transformation between them.
Recent studies have demonstrated the utility of engi-
neered surfaces[117,118] and heteronuclear seeds[119, 120] in crys-
tallizing specific polymorphs and discovering new ones. It is
possible that such approaches could be utilized to recover
polymorphs that had apparently “disappeared”.
The variety of circumstances and conditions for these
examples demonstrates that each molecule and each multi-
crystal form is unique. Recognizing the phenomenon of
disappearing polymorphs and learning to overcome and
control it requires a combination of considerable skill on
the part of the chemist with the acquisition of an intimate
familiarity with and understanding of the crystal chemistry of
the compound in question.
5. Outlook
It should be apparent from the content of this Review that
the mere existence of polymorphs and polymorphic trans-
formations is virtually impossible to predict, and that uncon-
trolled polymorphic conversions can have a severe impact on
the development of molecular materials for potential APIs
and speciality chemicals. Bearing in mind the advances made
in understanding some of the vagaries associated with the
solid state, it is sometimes difficult to comprehend why and
how new polymorphs still emerge (while others disappear)
long after crystal-form screens presumably have been com-
pleted. The point is that it can never be stated with certainty
that the most stable form has been found; at best it can be
determined which of the known forms is the most stable. As
the evidence above clearly shows, a new (and most often
more-stable) form can appear at any stage in the history of
a compound (or life-cycle of a drug).
Today we have access to highly sensitive analytical
instruments and automated polymorph screening platforms.
High-throughput salt and polymorph screens were “not on
the radar” 30–40 years ago, and the whole ethos surrounding
drug development was entirely different. In the experiences
of one of the authors of this review (R.W.L.) polymorph
Polymorphism
Angewandte
Chemie
6987Angew. Chem. Int. Ed. 2015, 54, 6972 – 6993 Ó 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
screens were actually carried out in the past by default, but
were not designated as such. During the course of research
and development of an API, a large team of highly skilled
chemists would fine-tune a process from an initial milligram
scale synthesis through scale-up, on to the pilot plant, and
ultimately into production. Within reason, time and resources
were not the issue. In terms of the pharmaceutical industry,
many drugs currently on the market and still highly profitable
were developed and produced in this “classic” way.
What has changed? The key differences affecting product
development these days are the compressed time scales for
drug development (surely at odds with the notion of kinetics
and crystallization?) and far fewer skilled process chemists
available to develop APIs in the manner described above. The
onus today is on efficiency and taking advantage of technical
developments that have appeared in the last decade or so.
Advances have been made based on the chemistry of the
particular compound in question, not least in the develop-
ment of automated polymorph screening platforms them-
selves, but also in the increasing sensitivity and precision of
automated analytical instrumentation, and in situ analysis and
algorithms for pattern recognition (e.g. comparisons of
diffraction patterns or Raman spectra).
There is no standard strategy or foolproof recipe for the
search for crystal forms. A combination of carefully designed
manually performed crystallization experiments combined
with automated high-throughput screens can reduce, but not
totally eliminate the likelihood of unexpected polymorphic
transformations if both highly pure and impure materials are
used. All readily accessible “significant” byproducts obtained
in the synthesis of a target compound should be considered
for use as seeds and additives. There is a need to screen for
possible polymorphic transformations under stressed condi-
tions (e.g. extreme humidity, temperature, and pressure) to
nurture confidence in the robustness of a product once it
leaves the realm of a controlled laboratory space. Further-
more, the screens and solid-state studies should be considered
throughout the lifetime of a drug or speciality chemical to
allow for the potential materialization of solid phases that
take considerable amounts of time to nucleate.
CSP[67,105,106] methods are now becoming progressively
more capable of guiding the search for new crystal
forms,[66, 121–127] and should be considered in solid-form screen-
ing processes, along with knowledge-based hydrogen-bond
propensity calculations,[128–131] whenever possible. Since CSP
was recently also successfully utilized to determine the crystal
structure of a sub-micrometer-sized crystallite (present in
picogram amounts) in a bulk consisting of a different
polymorph,[132] it is viable that CSP could aid the structural
characterizations of small molecular impurities that poten-
tially act as crystal seeds for the formation of unanticipated
crystal forms.
Processes associated with drug and speciality chemical
development have changed radically in the last decade or two.
Skills associated with particle engineering, drug design, and
even relatively “unfashionable” skills such as those concerned
with filtration and drying have advanced dramatically. All of
these process modifications involve perturbations that can
potentially lead to new solid phases.
Whilst advances in technologies associated with form
screening, analytical instrumentation, and in silico
approaches have come a long way, we are often forced to
return to the question of the level of better understanding of
the fundamentals associated with crystal nucleation and
growth. Will some (or many) of us still “get surprised” by
the vagaries of polymorphism and crystallization in 20 yearsÏ
time—or will it be all sorted out by then? There are still many
challenges and surprises in store.
Addendum
In the final section of this Review, we will present excerpts
from legal proceedings associated with the paroxetine hydro-
chloride case, with the aim of highlighting the complex
relationship between science and the law. Although no
scientific aspects of polymorphism are formally discussed,
we describe some additional important aspects of the
disappearing polymorph phenomenon.
As previously described, the PaxilÔ (paroxetine hydro-
chloride) litigation (SmithKline Beecham versus Apotex)
continued for nearly eight years before the US Supreme
Court refused to hear the case. The issues of seeding and
inherency, both intimately connected with disappearing
polymorphs were central to the case. In a number of instances,
the positions of the witnesses (as on record from trial
testimony) or of the judge (from his opinion in the first
instance) were not always precisely quoted or correctly
interpreted in secondary publications. In the interest of
informing the reader of how these issues can be interpreted
and misinterpreted as well as of setting the record straight, we
present some of that testimony and the way it was subse-
quently interpreted. Please note: one of us (J.B.) was a witness
at trial on behalf of SmithKline Beecham.
It will be recalled that Judge Posner found valid the patent
for which the independent Claim 1 is simply “Crystalline
paroxetine hydrochloride hemihydrate”. However, he also
found that Apotex would not be infringing that patent
because they would not be marketing an anhydrate API
with “high double-digit” percentages of the hemihydrate and
would be gaining nothing from the quantities of the hemi-
hydrate that he found would be in the Apotex product. In
what follows we relate the events subsequent to Judge
PosnerÏs ruling and how that ruling and the decisions from
the Federal Circuit (the venue for patent appeals) were
interpreted by the trade press and perhaps some of the
community not familiar with the details.
With regard to seeding, there was undisputed evidence
that Branford Chemicals (the Apotex subsidiary that actually
manufactured the API) started their research on the com-
pound with the hemihydrate, so that their facility was seeded
with Form 1. Judge Posner found that there would be
conversion of anhydrate into hemihydrate:
“Some conversion from anhydrate to hemihydrate is likely
to occur in a seeded facility in which the anhydrate is exposed
to air; BCIÏs plant is seeded; and the anhydrate manufactured
there is exposed to non-dehumidified air before it leaves the
plant. The evidence is sufficient to support an inference that
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BCI will be making at least tiny amounts of the hemihydrate if
it is permitted to manufacture the anhydrate.”
And Judge Posner then related to the amount of hemi-
hydrate and the ability to detect it:
“In sum, I am not persuaded that Apotex will produce an
anhydrate that has sufficient hemihydrate to be detectable by
the methods in use in 1985.”
1985 was the date of the application for the patent on the
hemihydrate, but it is unclear why he limited his analysis to
1985, as patent law does not limit the method of detection for
infringement purposes to those available at the time of the
invention, especially in this case where the claim simply
recites “Crystalline paroxetine hydrochloride hemihydrate”.
As discussed above, the Federal Circuit ultimately reversed
Judge Posner on his non-infringement determination, but
ultimately held the claim invalid as inherently anticipated.
In the course of the trial, Judge Posner asked counsel for
SmithKline Beecham whether a single crystal of the hemi-
hydrate in anhydrate API would infringe the patent. The
response was that in principle yes (in accord with the formal
reading of the patent law), but that the SmithKline Beecham
case was built on a considerable body of evidence that many
of ApotexÏs batches had converted and that, therefore, it was
highly likely that subsequent batches would exhibit conver-
sion—to an extent much greater than a single crystal and
proven as detectable by methods available in 2003.
On appeal, the Federal Circuit agreed with SmithKline
BeechamÏs claim construction:
“[N]othing in the Ð723 patent limits that structural com-
pound to its commercial embodiments,”
and thus overturned Judge Posner on that issue. More-
over, the Federal Circuit found that Apotex would be
infringing the Form 1 patent:
“Thus, reading Claim 1 in the context of the intrinsic
evidence, the conclusion is inescapable that the claim encom-
passes, without limitation, PHC [Paroxetine Hydrochloride]
hemihydrate—a crystal form of paroxetine hydrochloride that
contains one molecule of bound water for every two molecules
of paroxetine hydrochloride in the crystal structure.”
In other words, in principle, even a single crystal would
infringe the patent. Thus, the Federal Circuit agreed with
SmithKline Beecham that Apotex would infringe the patent.
Upon appeal to the Federal Circuit, two of ApotexÏs
arguments are relevant in the current context. First Apotex
attacked the decision acknowledging conversion as clearly
erroneous, and, second regarding seeding, they argued:
“In sum, the district courtÏs apparent fascination with the
seeding theory led it to a finding that smacks of alchemy, not
chemistry.”
At the time of the trial there was still a major misconcep-
tion about the meaning of a “disappearing polymorph”, as
evidenced by the courtroom exchange:
Question: “Okay. And, Dr. Bernstein, under your theory
that once hemihydrate was made, seeds of the hemihydrate
would contaminate any further paroxetine hydrochloride that
was made, then anyone practicing the Ð196 Ferrosan patent in
the United States would produce the hemihydrate after the
HP23 and 24 batches [SmithKline BeechamÏs first batches of
Form 1] were sent to the United States, correct?”
Answer: “No thatÏs not correct. That doesnÏt represent my
point of view. As you pointed out earlier, the last sentence in my
paper says once you have prepared it, you ought to be able to
prepare it again. So, I am not saying that the anhydrate canÏt be
prepared again. What I have said is that after the anhydrate is
prepared, if there are—if there are seeds around and water, then
it is highly likely that that will convert, and I think you have to
make a clear distinction between the preparation and the
conversion process. Those are two different processes. I never
said it couldnÏt be prepared.”
In April 2004, the Federal Circuit reversed Judge PosnerÏs
ruling and found that “any amount of crystalline paroxetine
hydrochloride hemihydrate without further limitation…will
infringe Claim 1.” However, it found Claim 1 was invalid
under a legal argument that the clinical trials that SmithKline
Beecham had carried out constituted a “public use.”
The concurring appellate judge in that decision also
expressed the view that Claim 1 was invalid because one
crystal form converted into a more stable crystal form without
human intervention, and was therefore a “naturally occurring
process”. However, the two other judges dismissed this view
because the crystal compound was a synthetic, man-made
compound, and thus is a “composition of matter” that is
eligible for patent protection.
This decision was appealed to the full court en banc
(fifteen judges) in June 2004. The full Court reversed the
“public use” issue and remanded the case back to the original
panel. In April 2005, the panel again found the claim invalid,
but this time on the grounds of inherent anticipation.
“Because the record contains clear and convincing evi-
dence that the production of PHC anhydrate in accordance
with the Ð196 [original Ferrosan anhydrate] patent inherently
results in at least trace amounts of PHC hemihydrate, this court
holds that the Ð196 patent inherently anticipates Claim 1 of the
Ð723 patent…”
It will be recalled that in US legal terms inherency means
invariably or inevitably. Hence, to reach such a conclusion the
Federal Circuit would have to be convinced that Form 1
existed before the SmithKline Beecham inventors said they
first detected it late in 1984. To examine the evidence for “at
least trace amounts of PHC hemihydrate” it is necessary to
return to the trial transcript and Judge PosnerÏs examination
of experts from both sides on this question.
The following is the related transcript excerpt of the
dialogue between Judge Posner and SmithKline BeechamÏs
expert:
Question: “I have a few questions, Dr. Bernstein. You said
on Friday that there was no hemihydrate before December,
1984. In fact, you said today that you are absolutely convinced
there was none. I donÏt understand that. I take it you mean there
was no detectable hemihydrate, donÏt you?”
Answer: “Well, your Honor, from the history subsequent to
December Ð84, when there were locations in which there was
definitely hemihydrate and there was water available, there was
almost, there was a high, very high probability of conversion.
So the fact that there was never any evidence of the hemi-
hydrate prior to 1984 and no evidence of conversion prior to
December of 1984 indicates to me that it didnÏt exist, and itÏs
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a situation similar to what I described in the case in my own
laboratory [in the 1995 review] .”
In fact, unchallenged data on accelerated stability tests of
the anhydrate at 40 8C and 75% relative humidity over
a period of several months in 1982 had exhibited no evidence
of any conversion into hemihydrate. Even Judge Posner
summarized in his decision:
“First, a batch of anhydrate manufactured by Ferrosan in
1980, though stored in a hot and humid place (the greater the
heat—short of the melting point, of course—and the humidity,
the likelier is conversion from the anhydrous to the hemi-
hydrous form), had three years later still not converted to the
hemihydrate form, suggesting that it had not been seeded and
hence that there were no seeds as late as 1980. And [pilot plant
batch] HP22, manufactured just weeks before HP23, con-
tained no detectable hemihydrate, whereas HP23 was entirely
hemihydrate.”
Judge Posner summarized the testimony of Terry Threl-
fall, ApotexÏs witness on this issue:
“Dr. Terence Threlfall, ApotexÏs expert on polymorphism,
testified to the contrary of Bernstein that anhydrous and
hemihydrous forms of paroxetine can coexist happily. There is
support for this conjecture in SmithKline BeechamÏs own
evidence, of whichmore later, that some of ApotexÏs anhydrous
product contains small amounts of hemihydrate without
conversion of the rest. In other words, as Threlfall testified,
a mixture of anhydrate and hemihydrate can be an equilibrium,
in which event the earliest batches of paroxetine manufactured
by Ferrosan may have contained undetectable quantities of the
hemihydrate. In light of this evidence, Dr. BernsteinÏs absolute
certainty that hemihydrate did not exist before December 1984
is not tenable. No one knows when the hemihydrate form of
paroxetine came into existence, although it is a reasonable
inference that it did not exist in a detectable amount until then.”
The opinion that the hemihydrate did not exist before
December 1984 may be untenable in Judge PosnerÏs view, but
there were absolutely no data or scientific evidence that it
ever existed before. Moreover, in light of the later observa-
tions about the tendency for conversion and the total lack
thereof in the 1980 batch strengthened that conviction. With
regard to the existence or non-existence of crystal forms, it
seems incontrovertible and contrary to the norms of scientific
reasoning that one can not claim to have a crystal form for
which there is—and up to a certain date has never been—
absolutely no physical or chemical evidence for its existence.
Especially in light of the results of the accelerated stability
tests, the fact that after the date of its appearance some
batches did not convert cannot serve as evidence that it
existed prior to its actual positive discovery late in 1984.
Furthermore, Judge Posner was discussing the situation
after December 1984 in which it was likely that there were
seeds of hemihydrate in locations where it have been
prepared. The lack of conversion, even in the presence of
seeds does not prove his point for the period prior to
December 1984. Conversion depended on the amount of
water (or humidity), temperature, and pressure. If the
combination of those factors was not sufficient, conversion
would not take place. In the 1980 accelerated stability tests on
a number of samples, they almost certainly would have been
sufficient.
This Addendum and some of the legal examples cited in
the text provide evidence for the complex relationship—
“uneasy bedfellows” in one view—between science and the
law, more specifically between the scientific method and
scientific reasoning on the one hand and legal reasoning on
the other hand. This dynamic relationship has been addressed
in a number of monographs[133–138] and will no doubt continue
to generate debate from practitioners and scholars of
jurisprudence and scientists.
For the scientific community, the standards have been well
stated by Peter Huber in the closing paragraph of one of his
treatises on the subject:
“The best test we have of certainty is good science—the
science of publication, replication, and verification, the science
of consensus and peer review; the science of Newton, Galileo,
and Gauss, Einstein, Feynman, Pasteur and Sabin; the science
that has eradicated smallpox, polio, and tuberculosis; the
science that has created antibiotics and vaccines. Or it is at least,
the best test of certainly so far devised by the mind of man.”[133]
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